Eric Lawitz

Summary

Publications

  1. doi request reprint Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics
    Eric Lawitz
    Alamo Medical Research, 621 Camden Street, San Antonio, TX 78215, United States Electronic address
    Antiviral Res 99:214-20. 2013
  2. doi request reprint A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients
    Eric J Lawitz
    Alamo Medical Research, San Antonio, TX, USA
    Antivir Ther 18:311-9. 2013
  3. doi request reprint A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
    Eric J Lawitz
    Alamo Medical Research, San Antonio, TX, USA
    J Hepatol 57:24-31. 2012
  4. pmc Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti
    Matthew J Hepburn
    Department of Medicine, Brooke Army Medical Center, San Antonio, Texas, USA
    BMC Gastroenterol 4:31. 2004
  5. pmc The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study
    Matthew J Hepburn
    Department of Medicine, Brooke Army Medical Center, Fort Sam, Houston, Texas, USA
    BMC Gastroenterol 5:14. 2005
  6. doi request reprint Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
    Eric Lawitz
    Alamo Medical Research, 621 Camden Suite 202, San Antonio, TX 78215, USA
    J Hepatol 49:163-9. 2008
  7. doi request reprint A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
    Eric Lawitz
    The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, United States
    J Hepatol 59:18-23. 2013
  8. doi request reprint Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
    Eric Lawitz
    Texas Liver Institute and the University of Texas Health Science Center, San Antonio, TX, USA Electronic address
    Lancet 383:515-23. 2014
  9. doi request reprint A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment
    Eric Lawitz
    Alamo Medical Research, San Antonio, TX, United States
    J Hepatol 59:11-7. 2013
  10. doi request reprint Sofosbuvir for previously untreated chronic hepatitis C infection
    Eric Lawitz
    Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX 78215, USA
    N Engl J Med 368:1878-87. 2013

Detail Information

Publications24

  1. doi request reprint Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics
    Eric Lawitz
    Alamo Medical Research, 621 Camden Street, San Antonio, TX 78215, United States Electronic address
    Antiviral Res 99:214-20. 2013
    ..Further development of vaniprevir, including studies in combination with other anti-HCV agents, is ongoing...
  2. doi request reprint A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients
    Eric J Lawitz
    Alamo Medical Research, San Antonio, TX, USA
    Antivir Ther 18:311-9. 2013
    ..GS-9451 is a novel inhibitor of the HCV NS3/4A protease and demonstrates potent in vitro suppression of HCV genotype 1 replicons...
  3. doi request reprint A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
    Eric J Lawitz
    Alamo Medical Research, San Antonio, TX, USA
    J Hepatol 57:24-31. 2012
    ..The safety, tolerability, pharmacokinetics, antiviral activity, and resistance profile of once-daily GS-5885 doses of 1-90 mg were evaluated in patients with chronic genotype 1 HCV...
  4. pmc Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti
    Matthew J Hepburn
    Department of Medicine, Brooke Army Medical Center, San Antonio, Texas, USA
    BMC Gastroenterol 4:31. 2004
    ..The purpose of this investigation was to determine the seroprevalence of hepatitis C and associated risk factors in an urban population in Haiti...
  5. pmc The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study
    Matthew J Hepburn
    Department of Medicine, Brooke Army Medical Center, Fort Sam, Houston, Texas, USA
    BMC Gastroenterol 5:14. 2005
    ..Our hypothesis was ultrasonography would perform poorly for the detection of steatosis outside of the context of a controlled study, primarily due to false-positive results caused by hepatic fibrosis and inflammation...
  6. doi request reprint Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
    Eric Lawitz
    Alamo Medical Research, 621 Camden Suite 202, San Antonio, TX 78215, USA
    J Hepatol 49:163-9. 2008
    ..This study assessed the safety and antiviral effects of telaprevir (VX-950) in combination with peginterferon alfa-2a and ribavirin...
  7. doi request reprint A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
    Eric Lawitz
    The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, United States
    J Hepatol 59:18-23. 2013
    ....
  8. doi request reprint Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
    Eric Lawitz
    Texas Liver Institute and the University of Texas Health Science Center, San Antonio, TX, USA Electronic address
    Lancet 383:515-23. 2014
    ....
  9. doi request reprint A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment
    Eric Lawitz
    Alamo Medical Research, San Antonio, TX, United States
    J Hepatol 59:11-7. 2013
    ....
  10. doi request reprint Sofosbuvir for previously untreated chronic hepatitis C infection
    Eric Lawitz
    Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX 78215, USA
    N Engl J Med 368:1878-87. 2013
    ..In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection...
  11. doi request reprint Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study
    Daniel E Brady
    Department of Medicine, Brooke Army Medical Center, San Antonio, Texas, USA
    Clin Gastroenterol Hepatol 8:66-71.e1. 2010
    ..Induction therapy with higher doses of PEG interferon may improve first-phase viral kinetics and thus improve the overall SVR in genotypes 1 and 4 patients...
  12. doi request reprint Exploratory study of oral combination antiviral therapy for hepatitis C
    Fred Poordad
    University of Texas Health Science Center at San Antonio, Division of Gastroenterology and Nutrition MC7878, 7703 Floyd Curl Dr, San Antonio, TX 78229, USA
    N Engl J Med 368:45-53. 2013
    ....
  13. doi request reprint Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    Eric Lawitz
    The Texas Liver Institute, San Antonio, TX, USA
    Lancet Infect Dis 13:401-8. 2013
    ..We assessed the safety and efficacy of sofosbuvir, a uridine nucleotide analogue, in treatment-naive patients with genotype 1-3 HCV infection...
  14. doi request reprint Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies
    Eric Lawitz
    Texas Liver Institute and the University of Texas Health Science Center, San Antonio, TX, USA
    Antivir Ther . 2016
    ....
  15. pmc Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
    Eric Lawitz
    Texas Liver Institute, San Antonio, TX University of Texas Health Science Center, San Antonio, TX
    Hepatology 61:769-75. 2015
    ..One patient discontinued study treatment because of an adverse event and four patients experienced serious adverse events. The most common adverse events were influenza-like illness, fatigue, anemia, and neutropenia...
  16. doi request reprint Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy
    Eric Lawitz
    Alamo Medical Research, San Antonio, TX, USA
    Antiviral Res 89:238-45. 2011
    ..600 mg or placebo bid for 14 days was then co-administered with pegylated interferon alpha (PEG-IFN-α) administered on days 1 and 8 to genotype 1 relapsers...
  17. pmc Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection
    Eric Lawitz
    Alamo Medical Research, Ltd, San Antonio, TX, USA
    Antimicrob Agents Chemother 57:1209-17. 2013
    ..GS-9851 was generally well tolerated, with no notable differences in adverse event frequency across doses. The pharmacokinetic profile observed in this study was similar to that seen in a single-ascending-dose study in healthy subjects...
  18. doi request reprint Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)
    Eric Lawitz
    Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX
    Hepatology 64:360-9. 2016
    ..Patient-reported outcomes improved from baseline to follow-up week 12...
  19. doi request reprint Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial
    Eric Lawitz
    The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX
    Hepatology . 2016
    ..Retreatment of the patients who failed short-duration therapy was achieved through extended treatment duration and addition of ribavirin. This article is protected by copyright. All rights reserved...
  20. doi request reprint Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C
    Eric Lawitz
    Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA
    Antivir Ther 20:699-708. 2015
    ..We evaluated the safety, pharmacokinetics and pharmacodynamics of GS-9620 in treatment-naive patients chronically infected with HCV genotype 1...
  21. doi request reprint Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection
    Eric Lawitz
    The Texas Liver Institute, University of Texas Health Science Center, 607 Camden, San Antonio, TX 78215, USA Electronic address
    J Infect 70:197-205. 2015
    ..To examine the safety and efficacy of ombitasvir and ABT-450 with ritonavir (ABT-450/r) ± ribavirin (RBV) in treatment-naïve, non-cirrhotic adults with chronic HCV genotype 1-3 infection...
  22. doi request reprint Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
    Eric Lawitz
    Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA Electronic address
    Lancet 384:1756-65. 2014
    ..Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and sofosbuvir...
  23. doi request reprint Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
    John M Vierling
    Baylor College of Medicine, Houston, TX, United States Electronic address
    J Hepatol 60:748-56. 2014
    ..We studied the efficacy of BOC/PR in patients with prior treatment failure, including those with a null response (<2-log10 decline in HCV RNA), to peginterferon/ribavirin...
  24. doi request reprint Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous
    Eric Lawitz
    Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA Electronic address
    Lancet 385:1075-86. 2015
    ....